Percutaneous nephrostomy in the management of advanced and terminal-stage gynecologic XXXX : outcome and complications.

@entity1 @entity43 @entity5 @entity1695 @entity189 @entity1458 @entity2629 @entity22097 @entity293 @entity1349
PURPOSE: The goal of the study was to evaluate the outcome and complications after percutaneous nephrostomy (PCN) insertion in advanced and terminal-stage gynecological @entity5 with @entity1695 ( @entity1695 ). MATERIALS AND METHODS: We analyzed data of 117 @entity1 with @entity1695 due to gynecological @entity5 , who had undergone PCN between 1996 and 2006. @entity5 was evidenced in 108 @entity1 , uterine @entity189 in six and @entity43 in three @entity1 . Eighty-nine had @entity1695 at the initial manifestation of the disease, 22 had persistent or recurrent @entity5 , and six were disease-free after initial therapy. @entity1458 was observed in 22.2% and creatine elevation in 79.5%. Mean follow-up was 11.43 months (range 0-112). RESULTS: The median age was 51 years (range 28-85). Bilateral nephrostomy was performed in 36.7% and unilateral in 63.3%. Renal function normalization occurred in 24.8%. @entity1349 ( @entity1349 ) was 16.8%. Higher @entity1349 occurred in @entity1 without initial @entity2629 versus those with @entity2629 (26.8% vs 13.9%). Median survival time for all the @entity1 was seven months, eight in primary cases versus six in recurrent ones, and eight months in @entity1 after initial therapy. Complications appeared in 53.85%. Most frequent were the loss of the nephrostomy catheter in 37.61% and @entity293 in 19.6%. CONCLUSION: Improvement of renal function after @entity22097 can be of clinical benefit in @entity1 who might be cured or for prolonged palliative care. @entity2629 seems to be poor prognostic sign.
